GAMMA Investing LLC Has $78,000 Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

GAMMA Investing LLC lifted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 184.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 430 shares of the company’s stock after purchasing an additional 279 shares during the quarter. GAMMA Investing LLC’s holdings in Krystal Biotech were worth $78,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Jamison Private Wealth Management Inc. acquired a new stake in Krystal Biotech during the 2nd quarter worth about $28,000. Key Financial Inc acquired a new stake in shares of Krystal Biotech during the 2nd quarter valued at about $28,000. Blue Trust Inc. lifted its holdings in shares of Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Krystal Biotech during the 2nd quarter valued at about $71,000. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Krystal Biotech by 11.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after buying an additional 94 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Citigroup reiterated a “neutral” rating and set a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright boosted their target price on Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Evercore ISI boosted their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Buy” and an average target price of $196.75.

Krystal Biotech Stock Down 0.6 %

Shares of NASDAQ KRYS opened at $178.46 on Wednesday. The business’s 50 day moving average is $186.75 and its two-hundred day moving average is $180.07. The company has a market cap of $5.10 billion, a P/E ratio of 95.43 and a beta of 0.82. Krystal Biotech, Inc. has a 12 month low of $93.95 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company’s revenue for the quarter was up 70283900.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.25) EPS. Sell-side analysts expect that Krystal Biotech, Inc. will post 3.13 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).